Taken together, our results showed that low-dose erastin treatment in cervical cancer cells not only induced ferroptosis but also led to ferroptosis resistance by increasing GCLM and GPX4, finally enhancing KRAS expression, indicating that mild ferroptosis induced anti-ferroptotic effects and thereby promoted tumorigenesis in cervical cancer cells. Here, KRAS is linked to cervical cancer.